Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Chief Scientific Officer | February 13, 2023 | February 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date February 13, 2023 · Filed February 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2033-02-13 | Direct | 1,400,000 |
Reported balance
After 2023-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-13 · Grant · Acquired 1,400,000 · Balance 1,400,000 F1: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 15, 2023 12:56 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 1,400,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-009635 · doc4.xml · derivative · entry 1 Brake Rachael Louise · CIK 0001898023 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:49 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 570,800 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-22-006511 · doc4.xml · derivative · entry 1 Brake Rachael Louise · CIK 0001898023 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,800 Underlying: Common Stock · 570,800 shares Expires 2032-02-01 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 16:04 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 500,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001209191-21-068508 · doc4.xml · derivative · entry 1 Brake Rachael Louise · CIK 0001898023 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-12-06 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on December 6, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on January 6, 2023. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on December 6, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on January 6, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.